THE IMPACT OF DONOR TYPE AND ABO INCOMPATIBILITY ON TRANSFUSION REQUIREMENTS AFTER NONMYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

被引：2
|
作者：
Wang, Z. [1 ]
Sorror, M. L. [1 ,2 ]
Leisenring, W. [1 ,3 ]
Schoch, G. [1 ]
Maloney, D. [1 ,2 ]
Sandmaier, B. M. [1 ,2 ]
Storb, R. [1 ,2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2009.12.323
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
281
引用
收藏
页码：S261 / S262
页数：2
相关论文
共 50 条
  • [41] Fludarabine pharmacokinetics in nonmyeloablative hematopoietic cell transplantation (HCT): Association with engraftment and neurotoxicty.
    Jacobson, PA
    Rogosheske, J
    Green, K
    Brunstein, C
    Barker, J
    Miller, J
    Wagner, J
    McGlave, P
    Tan, Y
    Weisdoff, D
    BLOOD, 2005, 106 (11) : 1023A - 1023A
  • [42] Anti-A Mediated Intravascular Hemolysis with Platelet Transfusion Following ABO Incompatible Hematopoietic Stem Cell Transplantation (HCT)
    Mills, A.
    Weiss, S.
    Hong, W.
    Ferrer, Z.
    Gonzalez, C.
    Viele, M.
    Goodnough, L. T.
    Fontaine, M.
    TRANSFUSION, 2011, 51 : 154A - 155A
  • [43] Nonmyeloablative unrelated donor hematopoietic cell transplantation (HCT) for patients (pts) with poor risk, relapsed or refractory multiple myeloma.
    Georges, GE
    Maris, MB
    Sandmaier, BM
    Shizuru, J
    Niederwieser, DW
    Agura, E
    Bruno, B
    McSweeney, PA
    Storb, RF
    Maloney, DG
    BLOOD, 2004, 104 (11) : 754A - 754A
  • [44] Does ABO incompatibility have an impact on outcome after allogeneic stem cell transplantation?
    Stamatovic, D.
    Tukic, L.
    Balint, B.
    Tarabar, O.
    Elez, M.
    Ostojic, G.
    Strnad, M.
    Tatomirovic, Z.
    Tasic, O.
    Marjanovic, S.
    Malesevic, M.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S430 - S430
  • [45] The influence of ABO incompatibility in transfusion requirements for patients diagnosed with primary immune deficiency treated with allogeneic stem cell transplantation
    Gasior, M.
    Humala, K.
    Guerrero, R.
    Rivas, I.
    Marcos, A.
    Arrieta, R.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S206 - S207
  • [46] Impact of graft composition on outcome after nonmyeloablative hematopoietic stem cell transplantation.
    Baron, F
    Frere, P
    Schaaf-Lafontaine, N
    Vanstraelen, G
    Baudoux, E
    Fillet, G
    Beguin, Y
    BLOOD, 2003, 102 (11) : 434B - 435B
  • [47] Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation
    Kim, JG
    Sohn, SK
    Kim, DH
    Baek, JH
    Lee, KB
    Min, WS
    Kim, CC
    Lee, MH
    Lee, JJ
    Chung, IJ
    Kim, HJ
    Lee, JW
    BONE MARROW TRANSPLANTATION, 2005, 35 (05) : 489 - 495
  • [48] Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation
    J G Kim
    S K Sohn
    D H Kim
    J H Baek
    K B Lee
    W S Min
    C C Kim
    M H Lee
    J-J Lee
    I-J Chung
    H-J Kim
    J W Lee
    Bone Marrow Transplantation, 2005, 35 : 489 - 495
  • [49] Considerations on "Impact of ABO-incompatibility on hepatocellular carcinoma recurrence after living donor liver transplantation"
    Gianardi, Desiree
    Ghinolfi, Davide
    Guadagni, Simone
    Morelli, Luca
    EJSO, 2019, 45 (04): : 715 - 716
  • [50] The impact of center accreditation on hematopoietic cell transplantation (HCT)
    S Marmor
    J W Begun
    J Abraham
    B A Virnig
    Bone Marrow Transplantation, 2015, 50 : 87 - 94
12345